Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience

IF 2.5 4区 医学 Q3 ONCOLOGY
Xue Song , Lijun Zhao , Ning Jiang, Naixin Ding, Dan Zong, Nan Zhang, Dejun Wang, Jing Wen, Xia He, Cheng Kong, Xiangzhi Zhu
{"title":"Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience","authors":"Xue Song ,&nbsp;Lijun Zhao ,&nbsp;Ning Jiang,&nbsp;Naixin Ding,&nbsp;Dan Zong,&nbsp;Nan Zhang,&nbsp;Dejun Wang,&nbsp;Jing Wen,&nbsp;Xia He,&nbsp;Cheng Kong,&nbsp;Xiangzhi Zhu","doi":"10.1016/j.currproblcancer.2023.100956","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Treatment-related toxicity following stereotactic ablative radiotherapy (SABR) in patients with central and ultracentral non-small cell lung cancer (NSCLC) is of potential concern, and the best regimens are still being explored. This study aimed to evaluate the clinical outcomes and toxicities of the patients with ultracentral and central NSCLC treated with SABR at our institution.</p></div><div><h3>Method</h3><p>This retrospective study included patients with central and ultracentral NSCLC treated with SABR to prescription doses of 50 Gy in five fractions, 56 Gy in seven fractions, or 60 Gy in ten fractionsat Jiangsu Cancer Hospital between May 2013 and October 2018. The patients were grouped as central or ultracentral tumors.Overall survival (OS), progression-free survival (PFS), and grade ≥3 toxicities were analyzed.</p></div><div><h3>Results</h3><p><span>Forty patients (31 male, nine female) were included. Median follow-up was 41 (5-81) months. The 1-, 2-, and 3-year OS rates were 90.0%, 83.6%, and 66.0%, respectively, and the 1-, 2-, and 3-year PFS rates were 82.5%, 62.9%, and 54.2%, respectively. OS in the ultracentral group was inferior compared with the central group (median, 52.0 months, 95%CI: 43.0-61.0 vs. not reached, P=0.03).The median PFS was 38.0 months in the ultracentral group (95%CI: 19.8-56.2) vs. not reached in the central group, although this difference was not statistically significant (P= 0.06). The overall incidence of grade ≥3 toxicity was five (12.5%) patients, (5 in the ultracentralgroup vs. 0 in the central group; P=0. 11), including one patient with grade 3 pneumonitis, two with grade 3 bronchial obstruction, one with grade 5 bronchial obstruction, and one with grade 5 </span>esophageal perforation.</p></div><div><h3>Conclusion</h3><p>Worse outcomes were obseverd in patients with ultracentral NSCLC than those with central tumors after SABR. Higher rate of treatment-related grade 3 or more toxicity was observed in the ultracentral group.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027223000090","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Treatment-related toxicity following stereotactic ablative radiotherapy (SABR) in patients with central and ultracentral non-small cell lung cancer (NSCLC) is of potential concern, and the best regimens are still being explored. This study aimed to evaluate the clinical outcomes and toxicities of the patients with ultracentral and central NSCLC treated with SABR at our institution.

Method

This retrospective study included patients with central and ultracentral NSCLC treated with SABR to prescription doses of 50 Gy in five fractions, 56 Gy in seven fractions, or 60 Gy in ten fractionsat Jiangsu Cancer Hospital between May 2013 and October 2018. The patients were grouped as central or ultracentral tumors.Overall survival (OS), progression-free survival (PFS), and grade ≥3 toxicities were analyzed.

Results

Forty patients (31 male, nine female) were included. Median follow-up was 41 (5-81) months. The 1-, 2-, and 3-year OS rates were 90.0%, 83.6%, and 66.0%, respectively, and the 1-, 2-, and 3-year PFS rates were 82.5%, 62.9%, and 54.2%, respectively. OS in the ultracentral group was inferior compared with the central group (median, 52.0 months, 95%CI: 43.0-61.0 vs. not reached, P=0.03).The median PFS was 38.0 months in the ultracentral group (95%CI: 19.8-56.2) vs. not reached in the central group, although this difference was not statistically significant (P= 0.06). The overall incidence of grade ≥3 toxicity was five (12.5%) patients, (5 in the ultracentralgroup vs. 0 in the central group; P=0. 11), including one patient with grade 3 pneumonitis, two with grade 3 bronchial obstruction, one with grade 5 bronchial obstruction, and one with grade 5 esophageal perforation.

Conclusion

Worse outcomes were obseverd in patients with ultracentral NSCLC than those with central tumors after SABR. Higher rate of treatment-related grade 3 or more toxicity was observed in the ultracentral group.

中央和超中央非小细胞肺癌患者接受立体定向放射治疗的长期结果:单机构经验
目的立体定向消融放疗(SABR)对中枢和超中枢非小细胞肺癌癌症(NSCLC)患者的治疗相关毒性是一个潜在的问题,最佳方案仍在探索中。本研究旨在评估在我们机构接受SABR治疗的超中枢性和中枢性NSCLC患者的临床结果和毒性。方法本回顾性研究纳入了2013年5月至2018年10月在癌症医院接受SABR治疗的中心性和超中心性NSCLC患者,处方剂量分别为5次50 Gy、7次56 Gy或10次60 Gy。将患者分为中心或超中心肿瘤。分析总生存期(OS)、无进展生存期(PFS)和≥3级毒性。结果纳入40例患者(男31例,女9例)。中位随访时间为41(5-81)个月。1、2和3年OS发生率分别为90.0%、83.6%和66.0%,1、2、3年PFS发生率分别是82.5%、62.9%和54.2%。与中心组相比,超中心组的OS较差(中位52.0个月,95%可信区间43.0-61.0与未达到,P=0.03)。超中心组中位PFS为38.0个月(95%可信区间19.8-56.2)与未达到中心组,尽管这一差异没有统计学意义(P=0.06)。≥3级毒性的总发生率为5名(12.5%)患者,(超中心组5例,中心组0例;P=0。11) ,包括1例3级肺炎,2例3级支气管阻塞,1例5级支气管阻塞和1例5期食管穿孔。结论SABR治疗后,超中心性NSCLC患者的预后比中心性肿瘤患者差。在超中枢组中观察到与治疗相关的3级或以上毒性发生率较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Problems in Cancer
Current Problems in Cancer 医学-肿瘤学
CiteScore
5.10
自引率
0.00%
发文量
71
审稿时长
15 days
期刊介绍: Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal''s scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Papers that focus solely on laboratory-based or basic science research are discouraged. The journal''s format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信